Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis

• Published in: Thrombosis research Vol. 208; pp. 190 - 197
• Main Authors: Bolzacchini, Elena, Pomero, Fulvio, Fazio, Martina, Civitelli, Chiara, Fabro, Giulia, Pellegrino, Domenico, Giordano, Monica, Squizzato, Alessandro
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01-12-2021
• Subjects: Arterial thromboembolism; Breast cancer; Breast Neoplasms - complications; Breast Neoplasms - drug therapy; CDK 4/6 inhibitors; Female; Humans; Thromboembolism - chemically induced; Thrombosis; Venous thromboembolism; Venous Thrombosis; Breast cancer; Arterial thromboembolism; CDK 4/6 inhibitors; Venous thromboembolism
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2021.11.009

Cyclin-dependent kinase inhibitors (CDKIs) may increase the risk of thrombotic events of endocrine therapy (ET) in women with hormone-sensitive, HER2-negative advanced breast cancer (BC). Aim of our systematic review is the estimate of the risk of venous and arterial thromboembolism in women with advanced BC treated with CDKIs in phase III randomized controlled trials (RCTs).
Studies were identified by electronic search of MEDLINE, EMBASE and CENTRAL database until October 2021. Risk of bias was assessed according to Cochrane criteria. Differences in thrombotic outcomes among groups were expressed as pooled odds ratio (OR) and corresponding 95% confidence interval (CI), which were calculated using both a fixed-effects and a random-effects model. Statistical heterogeneity was evaluated using the I2 statistic.
We included 7 phase III RCTs (4415 patients) for a total of 15 papers (7 were the first published paper and 8 the follow-up papers). Reporting of thrombotic events was at high risk of bias. Women with advanced BC treated with CDKIs and ET had a two to threefold increased risk of venous thromboembolic event (VTE) compared to ET plus placebo arm [OR 2.90 (95% CI 1.32, 6.37; I2 = 0%) in the main papers and OR 2.20 (95% CI 0.93, 5.20; I2 = 49%) in the follow-up papers]. Women with advanced BC treated with CDKIs and ET had a non-significant mild increased risk of arterial thromboembolic event compared to ET plus placebo arm [OR 1.22 (95% CI 0.47, 3.18 I2 = 0%)].
CDKIs in combination with endocrine therapy are associated with a two to threefold higher risk of VTE in comparison to endocrine therapy alone in women with advanced breast cancer, while the risk of arterial events is still to be defined.
•CDKIs in combination with endocrine therapy have completely changed the treatment strategy of ER positive, HER2 negative metastatic breast cancer.•CDKIs in combination with ET are associated with a two to threefold increased risk of VTEs in seven phase III RCTs (4415 patients)•Women treated with CDKIs should be aware of VTEs symptoms, oncologists should monitor their patients for VTEs during outpatients visits, and researcher should assess the potential benefit of thromboembolic prophylaxis in women with advanced BC treated with CDKIs judged at high risk of VTE.